Skip to main content

Gilead Sciences income statement

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

Gilead Sciences reported revenue of $29.4 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.4% from fiscal 2024. Net income was $8.51 billion and diluted earnings per share $6.78.

From Gilead Sciences's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Gilead Sciences income statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$4.23B$5.34B$7.01B$7.95B$8.39B$9.70B$11.20B$24.89B$32.64B$30.39B$26.11B$22.13B$22.45B$24.69B$27.30B$27.28B$27.12B$28.75B$29.44B$30.99B
Revenue growth—+26.1%+31.4%+13.4%+5.5%+15.7%+15.5%+122%+31.1%−6.9%−14.1%−15.2%+1.5%+10.0%+10.6%−0.1%−0.6%+6.0%+2.4%—
Cost of revenue$768.8M$1.13B$1.60B$1.87B$2.12B$2.47B$2.86B$3.79B$4.01B$4.26B$4.37B$4.85B$4.67B$4.57B$6.60B$5.66B$6.50B$6.25B$6.23B$6.22B
Gross profit$3.46B$4.21B$5.42B$6.08B$6.26B$7.23B$8.34B$21.10B$28.63B$26.13B$21.74B$17.27B$17.77B$20.12B$20.70B$21.62B$20.62B$22.50B$23.21B$24.77B
Gross margin81.8%78.9%77.2%76.5%74.7%74.5%74.5%84.8%87.7%86.0%83.3%78.1%79.2%81.5%75.8%79.3%76.0%78.3%78.8%79.9%
Research and development————$1.23B$1.76B$2.12B$2.85B$3.01B$5.10B$3.73B$5.02B$9.11B———————
Selling, general and administrative$705.7M$797.3M$946.7M$1.04B$1.24B$1.46B$1.70B$2.98B$3.43B$3.40B$3.88B$4.06B$4.38B$5.15B$5.25B$5.67B$6.09B$6.09B$5.77B$6.81B
Operating expenses————$2.47B$3.22B$3.82B$5.84B$6.44B$8.50B$7.61B$9.07B$13.49B———————
Operating income$2.16B$2.68B$3.53B$3.96B$3.79B$4.01B$4.52B$15.27B$22.19B$17.63B$14.12B$8.20B$4.29B$4.07B$9.92B$7.33B$7.61B$1.66B$10.02B−$2.36B
Operating margin51.2%50.2%50.3%49.8%45.2%41.3%40.4%61.3%68.0%58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%34.0%−7.6%
Interest expense$63.18M$65.24M$69.66M$109.0M$205.4M$361.0M$307.0M$412.0M$688.0M$964.0M$1.12B$1.08B$995.0M$984.0M$1.00B$935.0M$944.0M$977.0M$1.02B$1.01B
Other income and expense$109.8M$59.40M$42.40M$60.29M$66.58M−$37.00M−$9.00M$3.00M$154.0M$428.0M$523.0M$676.0M$1.87B−$1.42B−$639.0M−$581.0M$198.0M$6.00M$798.0M$841.0M
Income before tax$2.21B$2.67B$3.50B$3.91B$3.65B$3.61B$4.21B$14.86B$21.66B$17.10B$13.53B$7.80B$5.16B$1.67B$8.28B$5.81B$6.86B$690.0M$9.80B−$2.53B
Income tax expense$635.4M$702.4M$876.4M$1.02B$861.9M$1.04B$1.15B$2.80B$3.55B$3.61B$8.88B$2.34B−$204.0M$1.58B$2.08B$1.25B$1.25B$211.0M$1.29B$1.33B
Effective tax rate28.7%26.3%25.0%26.2%23.6%28.7%27.4%18.8%16.4%21.1%65.7%30.0%−4.0%94.7%25.1%21.5%18.2%30.6%13.1%−52.5%
Net income$1.58B$1.98B$2.64B$2.90B$2.80B$2.59B$3.08B$12.10B$18.11B$13.50B$4.63B$5.46B$5.39B$123.0M$6.22B$4.59B$5.67B$480.0M$8.51B−$3.86B
Net margin37.5%37.1%37.6%36.5%33.4%26.7%27.5%48.6%55.5%44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%−12.5%
EPS · diluted$0.82$1.03$1.41$1.66$1.77$1.64$1.81$7.35$11.91$9.94$3.51$4.17$4.22$0.10$4.93$3.64$4.50$0.38$6.78−$3.09
Diluted weighted average shares1.9B1.9B1.9B1.7B1.6B1.6B1.7B1.6B1.5B1.4B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B
Basic weighted average shares1.9B1.8B1.8B1.7B1.5B1.5B1.5B1.5B1.5B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.2B1.2B1.2B1.2B
EBITDA$2.20B$2.73B$3.59B$4.09B$3.93B$4.16B$4.63B$16.32B$23.29B$18.79B$15.41B$9.63B$5.69B$5.55B$11.95B$9.43B$10.30B$4.43B$12.78B$452.0M
EBITDA margin52.0%51.2%51.3%51.4%46.9%42.8%41.3%65.5%71.4%61.8%59.0%43.5%25.4%22.5%43.8%34.6%38.0%15.4%43.4%1.5%
Depreciation & amortization$36.89M$51.72M$64.56M$127.1M$141.8M$146.1M$103.0M$1.05B$1.10B$1.16B$1.29B$1.43B$1.40B$1.48B$2.03B$2.10B$2.69B$2.77B$2.76B$2.81B
Stock-based compensation$184.6M$153.4M$180.7M$200.0M$192.4M$209.0M$252.0M$360.0M$382.0M$380.0M$638.0M$845.0M$636.0M$643.0M$635.0M$637.0M$766.0M$835.0M$894.0M$913.0M
Dividends per share——————$0.00$0.00$1.29$1.84$2.08$2.28$2.52$2.72$2.84$2.92$3.00$3.08$3.16$3.25

Quarterly

Gilead Sciences income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$7.11B$6.69B$6.95B$7.54B$7.57B$6.67B$7.08B$7.77B$7.92B$6.96B$7.80B$8.30B
Cost of revenue$2.09B$1.55B$1.54B$1.57B$1.58B$1.54B$1.50B$1.57B$1.62B$1.45B$1.58B$1.57B
Gross profit$5.02B$5.13B$5.41B$5.97B$5.99B$5.13B$5.58B$6.20B$6.30B$5.51B$6.22B$6.73B
Gross margin70.6%76.8%77.8%79.1%79.1%76.9%78.8%79.8%79.5%79.2%79.8%81.1%
Selling, general and administrative$1.61B$1.38B$1.38B$1.43B$1.91B$1.26B$1.36B$1.36B$1.79B$1.45B$1.92B$1.64B
Operating income$1.61B−$4.32B$2.64B$888.0M$2.45B$2.24B$2.47B$3.33B$1.98B$2.59B−$10.39B$3.46B
Operating margin22.7%−64.6%38.0%11.8%32.4%33.6%34.9%42.8%25.0%37.2%−133%41.7%
Interest expense$252.0M$254.0M$237.0M$238.0M$249.0M$260.0M$254.0M$256.0M$255.0M$240.0M$247.0M$269.0M
Other income and expense$293.0M$91.00M−$355.0M$306.0M−$35.00M−$328.0M$208.0M$569.0M$349.0M$235.0M$387.0M−$130.0M
Income before tax$1.65B−$4.49B$2.05B$956.0M$2.17B$1.65B$2.43B$3.64B$2.08B$2.58B−$10.25B$3.06B
Income tax expense$237.0M−$315.0M$438.0M−$297.0M$385.0M$334.0M$468.0M$589.0M−$105.0M$559.0M$242.0M$634.0M
Effective tax rate14.3%7.0%21.3%−31.1%17.8%20.3%19.3%16.2%−5.1%21.7%−2.4%20.7%
Net income$1.43B−$4.17B$1.61B$1.25B$1.78B$1.31B$1.96B$3.05B$2.18B$2.02B−$10.50B$2.43B
Net margin20.1%−62.4%23.2%16.6%23.6%19.7%27.7%39.3%27.5%29.0%−135%29.3%
EPS · diluted$1.14−$3.34$1.29$1.00$1.39$1.04$1.56$2.43$1.74$1.61−$8.45$1.94
Diluted weighted average shares1.3B1.2B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.2B1.3B
Basic weighted average shares1.2B1.2B1.2B1.2B1.2B1.2B1.2B1.2B1.2B1.2B1.2B1.2B
EBITDA$2.30B−$3.63B$3.34B$1.58B$3.15B$2.93B$3.17B$4.01B$2.67B$3.27B−$9.70B$4.20B
EBITDA margin32.3%−54.3%48.0%20.9%41.6%44.0%44.7%51.7%33.7%47.1%−124%50.6%
Depreciation & amortization$688.0M$690.0M$694.0M$690.0M$693.0M$696.0M$691.0M$686.0M$687.0M$689.0M$698.0M$740.0M
Stock-based compensation$201.0M$187.0M$210.0M$216.0M$222.0M$209.0M$225.0M$230.0M$230.0M$218.0M$231.0M$234.0M
Dividends per share$0.75$0.77$0.77$0.77$0.77$0.79$0.79$0.79$0.79$0.82$0.82$0.82

The main figures as JSON and plain text. See data and methodology.

GILD in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.